Sanofi, Regeneron up the ante on PD-1 I/O program by a billion dollars
With pivotal trial work well in hand and high hopes to start grabbing approvals for the world’s sixth PD-1/L1 checkpoint drug this year, Sanofi and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
